

Analytical Methods

Accepted Manuscript



This article can be cited before page numbers have been issued, to do this please use: Z. Xue, B. Xu, C. Yang, X. L. Cui, J. Li, X. Shi and Y. Qiao, *Anal. Methods*, 2015, DOI: 10.1039/C5AY01289A.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Method Validation for the Analysis of *Licorice* Acid in the Blending Process by Near Infrared Diffuse Reflectance Spectroscopy

Zhong Xue^{a,b}, Bing Xu^{a,b*}, Chan Yang^{a,b}, Xianglong Cui^{a,b}, Jianyu Li^{a,b}, Xinyuan
Shi^{a,b}, Yanjiang Qiao^{a,b*}

^a Beijing University of Chinese Medicine, Beijing 100029, China

^b The Key Laboratory of TCM Information Engineering of State Administration of
Traditional Chinese Medicine, Beijing 100029, China

Abstract:

The present work described validation of near infrared (NIR) method for the quantification of the concentration of *Licorice* acid in the blending process of *Licorice* and talcum powder mixtures. The NIR diffuse reflectance spectra of samples were collected during the mixing process and the partial least square (PLS) model was developed. The accuracy profile (AP) approach that was fully compliant with the ICH Q2 (R1) guideline was used in order to assess the validity of the NIR chemometric method. Particularly, the β -content, γ -confidence tolerance interval, instead of β -expectation tolerance interval in the AP methodology, was introduced to provide a better estimate of measurement risk. The quantitative validation criteria such as trueness, precision (both repeatability and intermediate precision), results accuracy and valid range were obtained. The lower limit of quantification (LLOQ) was 1.26 mg·g⁻¹. Results demonstrated that NIR spectroscopy is suitable for the analysis of the concentration of *Licorice* acid. And the risk of using the established analytical method

* Corresponding authors at: Beijing University of Chinese Medicine, Beijing 100029, China. Tel.: +86 10 84738621; fax: +86 10 84738661.
E-mail addresses: xubing@bucm.edu.cn (B. Xu), yjqiao@263.net (Y. Qiao).

23 in routine phase could be well visualized and controlled.

24 **Key words:** NIR diffuse reflectance spectroscopy; Method validation; *Licorice* acid;
25 Accuracy profile; β -content, γ -confidence tolerance interval

27 1. Introduction

28 Near infrared (NIR) spectroscopy has become a widely used analytical technique
29 in pharmaceutical industry due to its high speed acquisition, non-destructive nature,
30 capacity to measure both physical and chemical properties, and the fact that it needs
31 little or no sample preparation[1]. Therefore, near infrared spectroscopy (NIRS) is
32 more and more considered as an attractive and promising analytical tool for process
33 analytical technology (PAT).

34 Once a calibration model for NIR analysis is developed and favorable
35 predictions are expected, the method must be validated to comply with regulatory
36 requirements. Like any analytical methods, the validation of NIRS method is a
37 mandatory step at the end of the method development in order to give enough
38 guarantees that each of future results during routine use will be close enough to the
39 true value [2].

40 Generally, validation strategies can be classified into two possible approaches:
41 the traditional approach and the accuracy profile approach. The traditional approach
42 relies on the validation of specific aspects of the method performance step by step,
43 such as accuracy, precision (repeatability and intermediate precision), linearity, range
44 of application, etc. These validation parameters are consistent with recommendations

1
2
3
4 45 of international conference of harmonization (ICH) and other regulatory guidelines
5
6 46 from EMA or FDA regulations. Examples of NIRS method validated following this
7
8 47 strategy can be found in the determination of water content or API (active
9
10 48 pharmaceutical ingredient) content of drug products[3-5], and in the quantification of
11
12 49 excipients of antifungal and antibacterial agents[6, 7]. But this type of validation is
13
14 50 time consuming and laborious. Furthermore, this strategy can be concluded wrongly
15
16 51 that a method giving imprecise results can be more easily validated than a precise one
17
18 52 [8].

19
20
21 53 The accuracy profile (AP) validation protocol was brought forward by the
22
23 54 SFSTP (La Societ  Francaise des Sciences et Techniques Pharmaceutiques) [9–11].
24
25 55 Accuracy profile is based on the combination in the same graph of the tolerance
26
27 56 interval and the acceptable limits, and circumvents some drawbacks of the traditional
28
29 57 validation procedures. Compared with the traditional approach, the accuracy profile
30
31 58 approach not only simplifies the validation process of an analytical procedure, but
32
33 59 also allows monitoring the risk of utilization. Moreover, it can declared an analytical
34
35 60 method is valid or not, and the analytical result is guaranteed to be fit for the intended
36
37 61 purpose of the analytical method [12, 13]. Several applications of NIR spectroscopy
38
39 62 used this approach can be found as follows. Schaefer used the accuracy profile
40
41 63 approach to validate the on-line NIR method to control an API crystallization step
42
43 64 [14]. Tomuta used this approach to demonstrate that the NIR chemometric methods
44
45 65 meet the requirements of a high throughput method for the determination of drug
46
47 66 content and pharmaceutical properties of indapamide tablets [15]. Wu successfully

1
2
3
4 67 used PLS model and accuracy profile method for accurate determination of
5
6 68 *chlorogenic* acid content in *L. japonica* solution in the ethanol precipitation process
7
8
9 69 [16]. Ziémons studied to develop a robust NIR calibration model to determine the
10
11 70 acetaminophen content of a low-dose syrup formulation, where the accuracy profile
12
13 71 confirmed the adequate accuracy of results generated by the method all over the
14
15 72 investigated API concentration range [17]. Fonteyne assessed the in-line moisture
16
17 73 content during the drying process in a six-segmented fluid bed dryer of a continuous
18
19 74 tablet production line by the accuracy profile, and it was statistically demonstrated
20
21 75 that the new NIR method performed at least as good as the Karl Fischer reference
22
23 76 method [18]. The AP validation strategy is also fully compliant with the ICH Q2 (R1)
24
25 77 guideline [12], and the prediction interval is built by the β -expectation tolerance
26
27 78 interval.

28
29 79 However, Saffaj recently reported that the β -expectation tolerance interval
30
31 80 cannot accurately predicted future measurements of the method in routine phase since
32
33 81 it was incapable to assess the routine uncertainty rightly and was unfortunately not
34
35 82 able to protect the laboratory and the client interests at the same time [20-22]. Since
36
37 83 the β -expectation tolerance interval only contains the information of trueness and
38
39 84 precision about the analysis method, it may underestimate the measurement risk.
40
41 85 While, the β -content, γ -confidence tolerance interval provides a good estimate of
42
43 86 measurement risk, and gives the best guarantees concerning the decision of declaring
44
45 87 a method as valid.

46
47 88 Therefore, in the present work, the β -content, γ -confidence tolerance interval is

1
2
3
4 89 recommended to build the accuracy profile for the validation of NIR analytical
5
6 90 method. And the NIR quantitative analysis of the concentration of *Licorice* acid in the
7
8 91 mixture of *Licorice* and talcum powder collected during the blending process was
9
10 92 taken as the research object. The aim of this study is to apply the new validation
11
12 93 strategy to study whether the NIR spectroscopy is suitable for the analysis of the
13
14 94 concentration of *Licorice* acid.
15
16 95

17 96 **2. Theory**

18 97 Accuracy profile is a graphical decision making tool aiming to help the analyst in
19 98 deciding whether an analytical procedure is valid. It is 2D-graphical representation
20 99 results for trueness, tolerance intervals and acceptance limits [8]. Whereas, validation
21 100 must cover up the whole application domain of the method. The trueness and
22 101 precision are needed to be calculated at each concentration levels. This ideal
23 102 acceptance criteria would ensure that a high proportion (say β) of future observations
24 103 lie within acceptance limits (say λ), with a high degree of confidence (say γ), where
25 104 the β -content, γ -confidence tolerance interval could help fulfill this task [29].

26 105 **2.1 Estimation of trueness and precision**

27 106 The $I \times J \times K$ full factorial validation protocol was utilized to design the validation
28 107 data set, where the effect of three aspects, i.e. conditions (I), the number of repetitions
29 108 (J) and level of concentrations (K) were taken into account [23]. The estimate of the
30 109 trueness and precision of the method was carried out at each of the considered k
31 110 concentration levels, using the following statistical model [11]:

$$Y_{ij} = \mu + \alpha_i + \varepsilon_{ij} \quad (i = 1, 2, \dots, m; j = 1, 2, \dots, n) \quad (1)$$

Where, Y_{ij} is the j -th measured value of the i -th condition at the concentration level k . μ is the mean of the measured values at each concentration level. m is the number of series, n is the number of independent replicates per series. α_i is the difference between the i -th series average and the μ at level k . α_i is considered as a normal random variable with 0 as the average and $\hat{\sigma}_B^2$ as the variance. ε_{ij} is the experimental error considered as a normal random variable with an average of 0 and a variance of $\hat{\sigma}_E^2$.

The experimental error is supposed to be independent of the series. The $\hat{\sigma}_B^2$ and $\hat{\sigma}_E^2$ variances represent the inter-series and intra-series variances, respectively. The restricted maximum likelihood method is used to estimate, at every concentration level, the parameters u_k , $\hat{\sigma}_B^2$ and $\hat{\sigma}_E^2$ of the model. Define MS_B and MS_E the mean square of inter-series and intra-series, respectively.

$$MS_B = \frac{n}{m-1} \sum_{i=1}^m (\bar{Y}_i - \bar{Y})^2 \quad (2)$$

$$\text{Where } \bar{Y}_i = \frac{1}{n} \sum_{j=1}^n Y_{ij}, \quad \bar{Y} = \frac{1}{mn} \sum_{i=1}^m \sum_{j=1}^n Y_{ij}$$

$$MS_E = \frac{1}{m(n-1)} \sum_{i=1}^m \sum_{j=1}^n (Y_{ij} - \bar{Y}_i)^2 \quad (3)$$

If $MS_E < MS_B$, then

$$\hat{\sigma}_B^2 = \frac{MS_B - MS_E}{n} \quad (4)$$

$$\hat{\sigma}_E^2 = MS_E \quad (5)$$

Otherwise

$$\hat{\sigma}_B^2 = 0 \quad (6)$$

$$\hat{\sigma}_E^2 = \frac{1}{mn-1} \sum_{i=1}^m \sum_{j=1}^n (Y_{ij} - \bar{Y})^2 \quad (7)$$

 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

133 **Precision:**

134 The ICH defines precision as the closeness of agreement between a series of
135 measurements obtained from multiple sampling of the same homogeneous sample
136 under the prescribed condition. Precision is evaluated at two levels: repeatability and
137 intermediate precision [19].

138 Repeatability expresses the precision under the same operating conditions over a
139 short interval of time, and should be assessed using a minimum of 9 determinations
140 covering the specified range for the procedure [12]. Therefore, the intra-series
141 variance in **Eq. (5)** or **Eq. (7)** provides the repeatability variance estimate:

$$142 \quad \text{Repeatability: } \hat{\sigma}_{Re}^2 = \hat{\sigma}_E^2 \quad (8)$$

143 Intermediate precision expresses within laboratories variations generated from
144 different equipment, different days or different analysts. The sum of intra- and
145 inter-series variance provides an estimation of the intermediate precision:

$$146 \quad \text{Intermediate precision: } \hat{\sigma}_M^2 = \hat{\sigma}_B^2 + \hat{\sigma}_E^2 \quad (9)$$

147 **Trueness:**

148 The trueness of an analytical procedure, also called theoretical true value,
149 express the closeness of agreement between the average of the results calculated by
150 the method and the accepted reference value [19]. The trueness is expressed as bias
151 and recovery in relative form.

$$152 \quad \text{bias}(\%) = \frac{\bar{Y} - X_r}{X_r} \times 100 \quad (10)$$

$$153 \quad \text{recovery}(\%) = \frac{\bar{Y}}{X_r} \times 100 \quad (11)$$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

154 Where, X_r is the theoretical value.

155 2.2 Estimation of the β -content, γ -confidence tolerance interval

156 The β -content, γ -confidence tolerance interval is defined as follows [24]:

$$157 P(P[L \leq x_i \leq U] \geq \beta) = \gamma \quad (12)$$

158 The β -content, γ -confidence tolerance interval provides lower (L) and upper (U)
159 limits that claim a specified proportion β of assayed values will lie within the interval
160 $[L, U]$, with specified confidence level γ . For example, for $\beta = 0.70$ and $\gamma = 0.95$, the
161 β -content, γ -confidence tolerance interval expresses that there is a probability (P) of
162 0.95 that 70% of the individual observations of the population are included in the
163 interval $[L, U]$.

164 According to the Mee's approach [25], the β -content, γ -confidence tolerance
165 interval under this method takes the following form:

$$166 [L, U] = [\bar{Y} - k_C \hat{\sigma}_M; \bar{Y} + k_C \hat{\sigma}_M] \quad (13)$$

167 With

$$168 k_C = \sqrt{\frac{\nu' \chi_{1;\beta}^2(\tau)}{\chi_{\nu';1-\gamma}^2}} \quad (14)$$

169 In **Eq. (13)**, k_C represents a Chi-square distribution associated with β and γ for
170 interval estimation [25]. $\chi_{1;\beta}^2(\tau)$ is the β quantile of a noncentral Chi-square
171 distribution with the degree of freedom 1. τ is noncentrality parameter. $\chi_{\nu';1-\gamma}^2$
172 denotes the 1- γ quantile of a non-central Chi-square distribution with degrees of
173 freedom ν' .

174 And

$$v' = \frac{(R'+1)^2}{(R'+(1/n))^2 / (m-1) + (1-(1/n)) / mn} \quad (15)$$

$$\tau = \frac{1}{mnB'} \quad (16)$$

$$R' = \max \left[0, \frac{1}{n} \left(\frac{F}{F_\eta} - 1 \right) \right] \quad (17)$$

$$\text{And } B' = \frac{R'+1}{nR'+1} \quad (18)$$

Where F is the mean square ratio MSb/MSe, and F_η is the 100 η percentile of an F distribution with $\nu_1 = m(n-1)$ and $\nu_2 = (m-1)$. However, based on numerical results, the recommended values of η are 0.85, 0.905 and 0.975, corresponding to $\gamma = 0.90$, 0.95 and 0.99, respectively [26].

Thus, the β -content, γ -confidence tolerance interval can be rewritten in relative form as follows:

$$[L(\%), U(\%)] = [\text{bias}(\%) - k_c RSD(\%), \text{bias}(\%) + k_c RSD(\%)] \quad (19)$$

Where:

$$RSD(\%) = \frac{\hat{\sigma}_M}{X_r} \times 100 \quad (20)$$

2.3 Establishment of the accuracy profile

The proposed building procedures of accuracy profile are as follows:

- 1) Set acceptance limits $(-\lambda, +\lambda)$.
- 2) Construct β -content, γ -confidence tolerance intervals ($[L, U]$ or $[L(\%), U(\%)]$) for each level according to **Eq. (13)** or **Eq. (19)** with desired confidence level γ
- 3) Make a 2D-graphical representation of results with the horizontal axis for the concentration levels and vertical axis for the tolerance interval limits (L, U) and accuracy.

196 4) Compare the tolerance interval limits (L , U) to the acceptance limits ($-\lambda$, $+\lambda$)

197 5) If (L , U) falls completely within ($-\lambda$, $+\lambda$), the method is accepted; otherwise,

198 the method is not accepted

199

200 3. Experimental

201 3.1 Materials

202 *Licorice* powder (lot number: 20120926) and medicinal talc (lot number:
203 20120514) were purchased from Ben Cao Fang Yuan Medicine Co., Ltd. (Beijing,
204 China). *Licorice* acid monoammonium salt (lot number: 111229) was supplied by
205 National Institutes for Food and Drug Control (Beijing, China). HPLC grade
206 methanol and phosphoric acid were purchased from Fisher Scientific (USA). HPLC
207 grade ammonium dihydrogen phosphate was purchased from Acros Organics (USA),
208 and the pure water was purchased from Wahaha Co., Ltd. (Hangzhou, China).

209 3.2 Acquisition of spectroscopic data

210 An Antaris near infrared spectrometer (Thermo Fisher Scientific Inc., USA) was
211 used to collect the spectroscopic data. Each spectrum was an average of 64 scans with
212 the resolution 8 cm^{-1} over the range $10000 \sim 4000\text{ cm}^{-1}$. A background spectrum was
213 taken daily in air. And the integrating sphere diffuse mode with rotating sample cup
214 was applied.

215 3.3 Reference method

216 The reference method used for the *Licorice* acid determination was HPLC assay
217 recommended by the Chinese Pharmacopoeia (Ch. P., 2010 Edition). An Agilent 1100
218 HPLC apparatus, equipped with a quaternary solvent delivery system, an auto sampler,

1
2
3
4 219 a DAD detector and HP workstation for data processing were used. The concentration
5
6 220 of *Licorice* acid was analyzed by the reverse phase chromatography on an Agilent
7
8
9 221 C18 column (4.6×250 mm, 5µm) with isocratic elution of the mobile phase consisted
10
11 222 of methanol, ammonium dihydrogen phosphate buffer (65:35, v/v) at the flow rate of
12
13 223 1.0 mL·min⁻¹. A column temperature of 30 °C, injection volume of 20 µL and
14
15
16 224 detection wavelength at 250 nm were used.

225 3.4 Calibration and validation protocols

17
18
19 226 The *licorice* and talcum powders with the mass ratio of 1:6 were mixed by the
20
21 227 10L three dimensional blender (ZNW-10, Beijing Xing Shi Li He Co., Ltd., China).
22
23 228 The filling coefficient was set at 70%, and the spindle speed was 13 rpm. During the
24
25 229 mixing process, the blender stopped at 5, 7, 9, 11, 12, 13, 14, 15, 17, 19 mins, and the
26
27 230 time required to reach a homogeneous blend is 17mins as assured by HPLC analysis.
28
29 231 And then, 5 g powders are respectively sampled at 5 positions preset, as shown in
30
31 232 **Fig.1**. These samples were directly analyzed by NIR under the conditions specified in
32
33 233 **Section 3.2**. Two batches of mixing experiments were carried out, and 100 (10×5×2)
34
35 234 samples were finally got.

235 Fig.1

36
37 236 The validation protocol used the 3×5×3 full factorial experiment design. Five
38
39 237 different *Licorice* acid concentrations levels (0.78 mg·g⁻¹, 1.56 mg·g⁻¹, 2.34 mg·g⁻¹,
40
41 238 3.12 mg·g⁻¹ and 3.89 mg·g⁻¹) were investigated, and each level was performed in 3
42
43 239 replicates on 3 different days, resulting in 45 samples in the validation set.

240 3.5 Data Processing

1
2
3
4 241 SIMCA-P 11.5 (Umetrics, US) and Unscrambler 7.0 (CAMO, Norway) were
5
6 242 used to perform spectral pretreatments. The PLS regression was performed on Matlab
7
8
9 243 version 7.0 (Math Works Inc., USA) with PLS Toolbox 2.1 (Eigenvector Research
10
11 244 Inc., USA). The calculation of the β -content, γ -confidence tolerance interval and the
12
13 245 construction of the accuracy profile were realized using homemade programs.
14
15
16 246

247 **4. Results and discussion**

248 **4.1 NIR method development**

17
18
19 249 Before model building, the first step of NIR method development is outlier
20
21 250 detection to improve the performance of the model. First, the raw NIR spectra of 100
22
23 251 samples were analyzed by the principal component analysis (PCA) with the first
24
25 252 principal components explaining 87.21% variation and the first two principal
26
27 253 components explaining the 99.8% variation of samples. Then, score plots with two
28
29 254 principal components are used to identify spectra clusters and to reveal the spatial
30
31 255 distribution of samples as shown in Fig. 2A. The Hotelling T^2 ellipse with 95%
32
33 256 confidence is calculated to identify the potential outliers as shown in Fig. 2B. As a
34
35 257 result, 4 abnormal samples were removed. And the rest 96 samples were divided into
36
37 258 the calibration set (56 samples) and the validation set (40 samples) by the
38
39 259 Kennard-Stone (K-S) method.
40
41
42
43
44
45
46
47
48
49
50

51 **Fig.2**

52
53
54 261 The second step for NIR method development is spectral pretreatment. In order
55
56 262 to improve the prediction ability of model, different spectral pretreatment methods
57
58
59
60

263 were investigated. Multiplicative signal correction (MSC) and standard normal variate
 264 (SNV) were used to eliminate the impact of light scattering generated by the uneven
 265 distribution of the particles size. The first derivative (1std) and second derivative
 266 (2ndd) treatments for spectral data were used to eliminate the spectral baseline drift,
 267 strengthen band characteristics and overcome overlapping bands. The Savitzky-Golay
 268 (S-G) smoothing and wavelet de-noising of spectra (WDS) were used to effectively
 269 smooth the high frequency noise, improve the signal to noise ratio and reduce the
 270 noise impact. For S-G smoothing, the filter width was set at 9 wavenumbers and the
 271 polynomial order was 2. And then, the optimal number of latent variable was
 272 optimized using the leave-one-out (LOO) cross validation method. Conventional
 273 correlation coefficient r for both calibration and validation sets, the root mean squared
 274 error of calibration (RMSEC), the root mean squared error of cross-validation
 275 (RMSECV), the root mean squared error of prediction (RMSEP) and ratio of
 276 performance deviation (RPD) were used to select several model candidates.

277 **Table 1** PLS model characteristics with and without preprocessed spectra.

| Pretreatment | LVs | Calibration set | | | | Validation set | | | |
|--------------|-----|-----------------|-------|--------|---------------------|----------------|-------|------|---------------------|
| | | r_{cal} | RMSEC | RMSECV | BIAS _{cal} | r_{val} | RMSEP | RPD | BIAS _{val} |
| Origin | 9 | 0.9932 | 0.085 | 0.134 | 0.068 | 0.9509 | 0.138 | 3.08 | 0.108 |
| S-G | 9 | 0.9921 | 0.092 | 0.136 | 0.072 | 0.9524 | 0.135 | 3.13 | 0.106 |
| 1std | 5 | 0.9956 | 0.068 | 0.162 | 0.056 | 0.9473 | 0.140 | 3.03 | 0.105 |
| 2ndd | 3 | 0.9757 | 0.160 | 0.187 | 0.118 | 0.9199 | 0.173 | 2.45 | 0.139 |
| S-G +1std | 8 | 0.9986 | 0.039 | 0.166 | 0.032 | 0.9495 | 0.139 | 3.06 | 0.099 |
| 1std+S-G | 5 | 0.9959 | 0.066 | 0.160 | 0.053 | 0.9492 | 0.137 | 3.10 | 0.101 |
| MSC | 9 | 0.9925 | 0.089 | 0.180 | 0.073 | 0.9464 | 0.144 | 2.95 | 0.114 |
| SNV | 9 | 0.9921 | 0.092 | 0.179 | 0.076 | 0.9462 | 0.144 | 2.95 | 0.115 |
| WDS | 10 | 0.9871 | 0.117 | 0.153 | 0.088 | 0.9431 | 0.141 | 3.00 | 0.108 |

278 Note: Origin means using the original spectra

1
2
3
4 279 As presented in **Table 1**, after spectral preprocessing, the prediction accuracy of
5
6 280 the model is not significantly improved. Compared to other preprocessing methods,
7
8 281 the 1std+S-G preprocessing method used relatively fewer PLS factors with values of
9
10 282 r_{cal} (0.9959) close to 1, and the smaller values of RMSEC (0.066 mg·g⁻¹), RMSECV
11
12 283 (0.160mg·g⁻¹) were also indications of the good quantitative performances of the
13
14 284 NIRS method developed. The RPD value 3.10 was greater than 3, demonstrating that
15
16 285 the predictive performance of the developed NIR calibration model was good.

17
18 286 Additionally, variables selection was done after preprocessing of spectra, but the
19
20 287 model performance did not improve (the data were shown in **Table S1** and the results
21
22 288 were shown in **Table S2**). Therefore, the 1std+S-G preprocessing method was chosen
23
24 289 to build the PLS regression model. **Fig.3A** showed that the model performance
25
26 290 changes with the latent variable (LV) factors. And it could be seen that the RMSEC
27
28 291 and RMSEP values did not change at 5 LVs, based on which the PLS model was
29
30 292 established. The relationship between the calibration set and the prediction set of the
31
32 293 regression model was shown in **Fig. 3B**.

33
34
35
36
37
38
39
40
41
42 **Fig. 3**

43 44 295 **4.2 NIR method validation**

45
46 296 In agreement with the guideline of ICH Q2, the typical validation characteristics
47
48 297 for assay procedures like accuracy, precision, range, and linearity were determined,
49
50 298 and the accuracy profile was established. Due to the quality control of traditional
51
52 299 Chinese medicine is similar to that of biological products, the acceptance limits ($-\lambda$,
53
54 300 $+\lambda$) were set at $\pm 20\%$ for the validation of the NIR method [11, 19, 20, 27]. To

1
2
3
4 301 compute the β -content, γ -confidence tolerance intervals and build the accuracy profile,
5
6 302 the present work had opted for the 4-6- λ rule adopted by the FDA for the validation of
7
8
9 303 bioanalytical procedures. And this rule was translated into $\beta = 66.7\%$ and $\gamma = 90\%$ by
10
11 304 Hoffman and Kringle [28-30].

305 4.2.1 Accuracy

306 Accuracy takes into account the total error which is the sum of systematic and
307 random errors, related to the validation result. As presented in **Table 2 and Fig. 4**, the
308 lower and upper β -content, γ -confidence tolerances for 1.56 mg·g⁻¹ (-1.82, 8.37), 2.34
309 mg·g⁻¹ (-12.2, 17.1), 3.12 mg·g⁻¹ (-6.20, 2.29), 3.89 mg·g⁻¹ (-19.4, 4.00) concentration
310 levels were all within the acceptance limits of $\pm 20\%$. Consequently, the method can
311 be considered as valid over the concentration range from 1.56 mg·g⁻¹ to 3.89 mg·g⁻¹.
312 Nevertheless, the accuracy was outside the acceptance limits for the level 0.78 mg·g⁻¹.
313 This result can be explained by: with a reduced concentration levels, system and
314 random errors would increase.

315 4.2.2 Precision

316 Precision is evaluated at two levels: repeatability and intermediate precision at
317 five concentration levels. The variance of repeatability and time dependent
318 intermediate precision as well as the relative standard deviation (RSD) were
319 calculated from estimated concentrations. From the precision results in **Table 2**, it is
320 obvious that the intermediate precision is worse than the repeatability, which means
321 that there is an important operator and/or day effect at these concentration levels. As
322 can be seen from **Fig. 4**, the dispersion of the results is good for 1.56 mg·g⁻¹, 2.34

323 $\text{mg}\cdot\text{g}^{-1}$, $3.12 \text{ mg}\cdot\text{g}^{-1}$ and $3.89 \text{ mg}\cdot\text{g}^{-1}$ concentration levels, leading to good
324 repeatability and intermediate precision values. However, with the decrease of
325 concentration, the repeatability and intermediate precision values significantly
326 increased. The values at the $0.78 \text{ mg}\cdot\text{g}^{-1}$ concentration level were too large to satisfy
327 the analytical requirements.

328 4.2.3 Range

329 The intersection between the accuracy profile and the acceptance limits defines
330 the lower limit of quantification (LLOQ) as well as the upper limit of quantification
331 (ULOQ) of the procedure. The lower and upper limits of quantification (LLOQ and
332 ULOQ) define the range where an analytical method is able to quantify accurately.
333 They are respectively the smallest and highest concentration levels where the
334 β -content, γ -confidence tolerance intervals are included within the acceptance limits.
335 If the β -content, γ -confidence tolerance intervals never cross the acceptance limits,
336 then the LLOQ and ULOQ are located at the beginning and at the end of the active
337 content range investigated.

338 In our case, the LLOQ value was $1.26 \text{ mg}\cdot\text{g}^{-1}$ via interpolation from the accuracy
339 profile (**Fig. 4**), and ULOQ value was $3.89 \text{ mg}\cdot\text{g}^{-1}$. So the quantitative range was
340 defined from $1.26 \text{ mg}\cdot\text{g}^{-1}$ to $3.89 \text{ mg}\cdot\text{g}^{-1}$.

341 **Table 2** ICH Q2 (R1) validation criteria for the NIR method

| Level ($\text{mg}\cdot\text{g}^{-1}$) | Mean calculated concentration | Trueness | | Precision | | Accuracy | |
|--|-------------------------------------|----------------------|-----------------|----------------------|----------------------------------|------------------|------------------|
| | | Relative bias (%) | Recovery (%) | Repeatability (%) | Intermediate precision (%) | β -CTI (%) | Abs β -CTI |
| 0.78 | 0.65 | -16.8 | 83.2 | 9.82 | 11.7 | [-48.9,15.3] | [0.40,0.90] |
| 1.56 | 1.61 | 3.28 | 103.3 | 2.87 | 2.87 | [-1.82,8.37] | [1.53,1.69] |

 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| | | | | | | | |
|------|------|-------|-------|------|------|--------------|-------------|
| 2.34 | 2.40 | 2.47 | 102.5 | 2.45 | 4.53 | [-12.2,17.1] | [2.05,2.74] |
| 3.12 | 3.06 | -1.96 | 98.0 | 1.40 | 1.60 | [-6.20,2.29] | [2.93,3.19] |
| 3.89 | 3.59 | -7.68 | 92.3 | 1.51 | 3.50 | [-19.4,4.00] | [3.14,4.05] |

342 Note: The β -CTI (%) is relative β -content, γ -confidence tolerance interval; Abs β -CTI is absolute
343 β -content, γ -confidence tolerance interval.

344 **Fig.4**

345 4.2.4 Linearity

346 The linearity of an analytical method is its ability within a definite range to
347 obtain results directly proportional to the concentrations (quantities) of the analyte in
348 the sample. Therefore, a linear model was fitted on the calculated concentrations of
349 the validation standards for all series as a function of the introduced concentrations.

350 The relationship between the NIR predictions and the theoretical values was
351 evaluated by the linear equation: $y = 0.9426 \times x + 0.0572$ with R^2 of 0.9820. The
352 intercept, the slope and the R^2 values demonstrated good agreement between the NIR
353 predictions and the theoretical values. In order to prove the method linearity, the
354 absolute β -content, γ -confidence tolerance intervals were applied. The linearity over
355 the *Licorice* acid content range 1.56~3.89 mg·g⁻¹ was demonstrated since the
356 β -content, γ -confidence tolerance interval ($\gamma = 90\%$) limits were within the absolute
357 acceptance limits as shown in **Fig. 5**.

358 **Fig.5**

359 5. Conclusion

360 In this paper, a new strategy based on the accuracy profile methodology which
361 incorporates the β -content, γ -confidence tolerance interval has been successfully
362 managed to validate the NIR quantitative analytical procedures in a traditional

1
2
3
4 363 Chinese medicine blending process. Results demonstrated the developed NIR method
5
6 364 was suitable for the analysis of the concentration of *Licorice* acid. The proposed
7
8
9 365 approach offered a formal statistical framework by which the performance of the
10
11 366 method was assessed. The method validation characteristics such as accuracy,
12
13 367 precision, range, linearity and limit of quantification could be obtained for customers.
14
15 368 In addition, the improved accuracy profile approach gave a good estimate of
16
17 369 measurement risk, and provided visual and reliable method decision tool in the
18
19 370 validation stage and controlled the risk of using the analytical method in routine phase.
20
21 371 Moreover, it is believed that the improved accuracy profile approach is not only
22
23 372 suitable for NIR method, but can also be used for other analytic procedures.
24
25
26
27
28
29
30
31
32

374 Acknowledgement

375 This work is supported by Beijing Natural Science Foundation (No. 7154217)
376 and the Joint Development Program Supported by Beijing Municipal Education
377 Commission - Key Laboratory Construction Project (Study on the Integrated
378 Modeling and Optimization Technology of the Chained Pharmaceutical Process of
379 Chinese Medicine Products.


381 References

- 382 [1] M. Jamrógiewicz, Application of near-infrared spectroscopy in the pharmaceutical technology, J.
383 Pharm. Biomed. Anal. 66 (2012) 1-10.
384 [2] C. De Bleye, P.F. Chavez, J. Mantanus, R. Marini, P. Hubert, E. Rozet, E. Ziemons, Critical review
385 of near-infrared spectroscopic methods validations in pharmaceutical applications, J. Pharm. Biomed.
386 Anal. 69 (2012) 125-132.
387 [3] A. Peinado, J. Hammond, A. Scott, Development, validation and transfer of a near infrared method
388 to determine in-line the end point of a fluidised drying process for commercial production batches of an
389 approved oral solid dose pharmaceutical product, J. Pharm. Biomed. Anal. 54 (2011) 13-20.

- 1
2
3 390 [4] X. Wang, Q. Fu, J. Sheng, X. Yang, J. Jia, W. Du, Construction of a universal quantitative model for
4 391 ibuprofen sustained-release capsules from different manufacturers using near-infrared diffuse reflection
5 392 spectroscopy, *Vib. Spectrosc.* 53 (2010) 214-217.
- 6
7 393 [5] Y.Y. Liu, C.Q. Hu, Construction of predictive models for gentamicin contents in aqueous solution
8 394 using specific near infrared spectral regions, *Vib. Spectrosc.* 55 (2011) 241-249.
- 9
10 395 [6] M. Blanco, M. Alcalá, M. Bautista, Pharmaceutical gel analysis by NIR spectroscopy:
11 396 determination of the active principle and low concentration of preservatives, *Eur. J. Pharm. Sci.* 33
12 397 (2008) 409-414.
- 13
14 398 [7] S.C. Baratieri, J.M. Barbosa, M.P. Freitas, J.A. Martins, Multivariate analysis of nystatin and
15 399 metronidazole in semi-solid matrix by means of diffuse reflectance NIR spectroscopy and PLS
16 400 regression, *J. Pharm. Biomed. Anal.* 40 (2006) 51-55.
- 17
18 401 [8] Max Feinberg, Validation of analytical methods based on accuracy profiles, *J. Chromatogr. A*, 1158
19 402 (2007) 174-183
- 20
21 403 [9] P. Hubert, J. J. Nguyen-Huu, B. Boulanger, E. Chapuzet, P. Chiap, N. Cohen, P. A. Compagnon, W.
22 404 Dewé, M. Feinberg, M. Lallier, M. Laurentie, N. Mercier, G. Muzard, C. Nivet, L. Valat,
23 405 Harmonization of strategies for the validation of quantitative analytical procedures: A SFSTP
24 406 proposal—part I, *J. Pharm. Biomed. Anal.* 36 (2004) 579-586.
- 25
26 407 [10] Ph. Hubert, J. J. Nguyen-Huu, B. Boulanger, E. Chapuzet, P. Chiap, N. Cohen, P. A. Compagnon,
27 408 W. Dewé, M. Feinberg, M. Lallier, M. Laurentie, N. Mercier, G. Muzard, C. Nivet, L. Valat, E. Rozet,
28 409 Harmonization of strategies for the validation of quantitative analytical procedures A SFSTP proposal –
29 410 Part II, *J. Pharm. Biomed. Anal.* 45 (2007) 70-81.
- 30
31 411 [11] Ph. Hubert, J. J. Nguyen-Huu, B. Boulanger, E. Chapuzet, N. Cohen, P. A. Compagnon, W.
32 412 Dewé, M. Feinberg, M. Laurentie, N. Mercier, G. Muzard, L. Valat, E. Rozet, Harmonization of
33 413 strategies for the validation of quantitative analytical procedures A SFSTP proposal—Part III, *J. Pharm.*
34 414 *Biomed. Anal.* 45 (2007) 82-96.
- 35
36 415 [12] E. Rozet, A. Ceccato, C. Hubert, E. Ziemons, R. Oprean, S. Rudaz, B. Boulanger, Ph. Hubert,
37 416 Analysis of recent pharmaceutical regulatory documents on analytical method validation, *J.*
38 417 *Chromatogr. A* 1158 (2007) 111-125.
- 39
40 418 [13] E. Rozet, E. Ziemons, R.D. Marini, B. Boulanger, Ph. Hubert, Comments on uncertainty profiles
41 419 for the validation of analytical methods by Saffaj and Ihssane, *Talanta* 88 (2012) 769-771.
- 42
43 420 [14] C. Schaefer, D. Clicq, C. Lecomte, A. Merschaert, E. Norrant, F. Fotiadu, A Process Analytical
44 421 Technology (PAT) approach to control a new API manufacturing process: Development, validation and
45 422 implementation. *Talanta* 120 (2014) 114-125.
- 46
47 423 [15] I. Tomuta, L. Rus, R. Iovanov, L. L.Rus, High-throughput NIR-chemometric methods for
48 424 determination of drug content and pharmaceutical properties of indapamide tablets. *J. Pharm. Biomed.*
49 425 *Anal.* 84 (2013) 285-292.
- 50
51 426 [16] Z. S. Wu, B. Xu, M. Du, C. L. Sui, X.Y. Shi, Y. J. Qiao, Validation of a NIR quantification method
52 427 for the determination of chlorogenic acid in *Lonicera japonica* solution in ethanol precipitation process.
53 428 *J. Pharm. Biomed. Anal.* 62 (2012) 1-6.
- 54
55 429 [17] E. Ziémons, J. Mantanusa, P. Lebruna, E. Rozeta, B. Evrardb, Ph. Huberta, Acetaminophen
56 430 determination in low-dose pharmaceutical syrup by NIR spectroscopy, *J. Pharm. Biomed. Anal.* 53
57 431 (2010) 510-516.
- 58
59 432 [18] M. Fonteyne, J. Arruabarrena, J. de Beer, M. Hellings, T. V. Den Kerkhof, A. Burggraeve, C.
60 433 Vervaet, J. Paul Remon, T. De Beer, NIR spectroscopic method for the in-line moisture assessment

- 1
2
3 434 duringdrying in a six-segmented fluid bed dryer of a continuous tablet production line: Validation of
4 435 quantifying abilities and uncertainty assessment, *J. Pharm. Biomed. Anal.* 100 (2014) 21-27.
5 436 [19] International Conference on Harmonization (ICH), Validation of analytical procedures: text and
6 437 methodology, Q2 (R1), 2005.
7 438 [20] T. Saffaj, B. Ihssane, Uncertainty profiles for the validation of analytical methods, *Talanta* 85
8 439 (2011) 1535-1542.
9 440 [21] T. Saffaj, B. Ihssane, Response to comments on “Uncertainty profiles for the validation of
10 441 analytical methods”, *Talanta* 94 (2012) 361-362.
11 442 [22] T. Saffaj, B. Ihssane, Remarks on “Reply to the responses to the comments on “uncertainty
12 443 profiles for the validation of analytical methods” by Saffaj and Ihssane”, *Talanta* 106 (2013) 155-157.
13 444 [23] B. Govaerts, W. Dewé, M. Maumy, B. Boulanger, Pre-study analytical method validation:
14 445 comparison of four alternative approaches based on quality-level estimation and tolerance intervals,
15 446 *Qual. Reliab. Engng. Int.* 24 (2008) 667-680
16 447 [24] P. M. Kulkarni, D. Kushary, β -expectation and β -content tolerance intervals for dependent
17 448 observations, *Commun. Stat-Theor. M.* 20 (1991) 1043-1054.
18 449 [25] R. Mee, β -Expectation and β -Content Tolerance Limits for Balanced One-Way ANOVA Random
19 450 Model *Technometrics*, 26 (1984) 251-254.
20 451 [26] T. Saffaj, B. Ihssane, F. Jhilal, H. Bouchafra, S. Laslami, S. A. Sosse, An overall uncertainty
21 452 approach for the validation of analytical separation methods, *Analyst* 38 (2013) 4677-4691.
22 453 [27] Z. Xue, B. Xu, Q. Liu, X. Y. Shi, J. Y. Li, Z. S. Wu, Y. J. Qiao, Application of uncertainty
23 454 assessment in NIR quantitative analysis of Traditional Chinese Medicine, *Spectrosc. Spect. Anal.* 34
24 455 (2014) 2657-2661.
25 456 [28] D. Hoffman, R. Kringle, Two-sided tolerance intervals for balanced and unbalanced random
26 457 effects models, *J. Biopharm. Stat.* 15 (2005) 283-293.
27 458 [29] D. Hoffman, R. Kringle, A total error approach for the validation of quantitative analytical
28 459 methods, *Pharma Research*, 24 (2007) 1157-1164.
29 460 [30] D. Hoffman, Statistical considerations for assessment of bioanalytical incurred sample
30 461 reproducibility, *AAPS J.* 11 (2009) 570-580.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Graphical Abstract



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure captions

1
2
3
4
5
6
7 **Figure 1** Blend equipment and sampling points.

8
9 **Figure 2** **A** Scores plot; **B** Outliers detection by the Hotelling T^2 ellipse.


10
11 **Figure 3** **A** Calibration characteristics vs. number of latent factors; **B** Correlation graph of NIR
12
13 predictive values with reference values.

14
15
16 **Figure 4** Accuracy profile for the *Licorice* acid content. The red line is the relative bias; the medium
17
18 dashed lines are the β -content; γ -confidence tolerance intervals ($\gamma = 90\%$) and the red short dashed lines
19
20 are the acceptance limits ($\pm 20\%$), the 9 black points at each concentration level are relative bias for each
21
22 predictive value.

23
24
25 **Figure 5** Linear profile for NIR analysis of the *Licorice* acid content. The blue medium dashed lines are
26
27 absolute β -content, γ -confidence tolerance intervals ($\gamma = 90\%$), and red short dashed lines represent the
28
29 accepted limits at $\pm 20\%$. The continuous line is the identity line $y = x$.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Fig.1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fig.2

A



B





Fig.3

A



B




Fig.4





Fig.5



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60